ABSK043
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for ABSK043, covering 2024-11-19 to 2025-09-11. Get the full timeline:
Most recent: Clinical Trial Update: A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas [Phase 2]